Brainstorm Cell Therapeutics (NASDAQ:BCLI) Stock Rating Upgraded by StockNews.com

Brainstorm Cell Therapeutics (NASDAQ:BCLI) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a report released on Monday.

Brainstorm Cell Therapeutics Stock Down 5.0 %

NASDAQ:BCLI traded down $0.10 during trading hours on Monday, hitting $1.89. 77,517 shares of the stock were exchanged, compared to its average volume of 104,362. The company has a market capitalization of $10.77 million, a P/E ratio of -0.39 and a beta of 0.29. The company’s 50 day moving average is $1.81 and its two-hundred day moving average is $3.12. Brainstorm Cell Therapeutics has a twelve month low of $1.05 and a twelve month high of $11.89.

Institutional Investors Weigh In On Brainstorm Cell Therapeutics

A hedge fund recently bought a new stake in Brainstorm Cell Therapeutics stock. Armistice Capital LLC acquired a new position in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 7,917,653 shares of the biotechnology company’s stock, valued at approximately $2,680,000. Armistice Capital LLC owned approximately 11.30% of Brainstorm Cell Therapeutics as of its most recent filing with the Securities & Exchange Commission. 14.33% of the stock is owned by institutional investors and hedge funds.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.